Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

References for PMC Articles for PubMed (Select 20306175)

1.

Cross-validation of a new procedure for early screening of smoking cessation medications in humans.

Perkins KA, Lerman C, Fonte CA, Mercincavage M, Stitzer ML, Chengappa KN, Jain A.

Clin Pharmacol Ther. 2010 Jul;88(1):109-14. doi: 10.1038/clpt.2010.65. Epub 2010 May 19.

PMID:
20485335
2.

The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats.

O'Connor EC, Parker D, Rollema H, Mead AN.

Psychopharmacology (Berl). 2010 Feb;208(3):365-76. doi: 10.1007/s00213-009-1739-5. Epub 2009 Dec 5.

PMID:
19967529
3.

Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans.

Sofuoglu M, Herman AI, Mooney M, Waters AJ.

Psychopharmacology (Berl). 2009 Nov;207(1):153-62. doi: 10.1007/s00213-009-1643-z. Epub 2009 Aug 20.

4.

Varenicline improves mood and cognition during smoking abstinence.

Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC, Frey JM, Siegel S, Lerman C.

Biol Psychiatry. 2009 Jan 15;65(2):144-9. doi: 10.1016/j.biopsych.2008.08.028. Epub 2008 Oct 8.

5.

The influence of acute varenicline administration on smoking and eating behavior in humans.

Stoops WW, Vansickel AR, Glaser PE, Rush CR.

Pharmacol Biochem Behav. 2008 Nov;91(1):165-9. doi: 10.1016/j.pbb.2008.07.001. Epub 2008 Jul 13.

PMID:
18675291
6.

Development of procedures for early screening of smoking cessation medications in humans.

Perkins KA, Lerman C, Stitzer M, Fonte CA, Briski JL, Scott JA, Chengappa KN.

Clin Pharmacol Ther. 2008 Aug;84(2):216-21. doi: 10.1038/clpt.2008.30. Epub 2008 Mar 19.

PMID:
18388880
7.

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial.

Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, Williams KE, Reeves KR.

Thorax. 2008 Aug;63(8):717-24. doi: 10.1136/thx.2007.090647. Epub 2008 Feb 8.

8.

Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.

West R, Baker CL, Cappelleri JC, Bushmakin AG.

Psychopharmacology (Berl). 2008 Apr;197(3):371-7. Epub 2007 Dec 15.

PMID:
18084743
9.

Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD 3rd, Williams KE.

Neuropharmacology. 2007 Mar;52(3):985-94. Epub 2006 Dec 8.

PMID:
17157884
10.

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.

Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K.

Arch Intern Med. 2006 Aug 14-28;166(15):1571-7.

PMID:
16908789
11.

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group.

JAMA. 2006 Jul 5;296(1):56-63. Erratum in: JAMA. 2006 Sep 20;296(11):1355.

PMID:
16820547
12.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group.

JAMA. 2006 Jul 5;296(1):47-55.

PMID:
16820546
13.

Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.

Mihalak KB, Carroll FI, Luetje CW.

Mol Pharmacol. 2006 Sep;70(3):801-5. Epub 2006 Jun 9.

14.

Immediate hedonic response to smoking lapses: relationship to smoking relapse, and effects of nicotine replacement therapy.

Shiffman S, Ferguson SG, Gwaltney CJ.

Psychopharmacology (Berl). 2006 Mar;184(3-4):608-18. Epub 2005 Nov 11.

PMID:
16283258
15.

Medication screening for smoking cessation: a proposal for new methodologies.

Perkins KA, Stitzer M, Lerman C.

Psychopharmacology (Berl). 2006 Mar;184(3-4):628-36. Epub 2005 Sep 15. Review.

PMID:
16163529
16.

Prospective examination of effects of smoking abstinence on cortisol and withdrawal symptoms as predictors of early smoking relapse.

al'Absi M, Hatsukami D, Davis GL, Wittmers LE.

Drug Alcohol Depend. 2004 Mar 8;73(3):267-78.

PMID:
15036549
17.

Subjective effects of an initial dose of nicotine nasal spray predict treatment outcome.

Kaufmann V, Jepson C, Rukstalis M, Perkins K, Audrain-McGovern J, Lerman C.

Psychopharmacology (Berl). 2004 Mar;172(3):271-6. Epub 2003 Nov 25.

PMID:
14647969
18.

Acute nicotine reinforcement, but not chronic tolerance, predicts withdrawal and relapse after quitting smoking.

Perkins KA, Broge M, Gerlach D, Sanders M, Grobe JE, Cherry C, Wilson AS.

Health Psychol. 2002 Jul;21(4):332-9.

PMID:
12090675
19.

The cigarette pack as image: new evidence from tobacco industry documents.

Wakefield M, Morley C, Horan JK, Cummings KM.

Tob Control. 2002 Mar;11 Suppl 1:I73-80.

20.

Acute doses of d-amphetamine and bupropion increase cigarette smoking.

Cousins MS, Stamat HM, de Wit H.

Psychopharmacology (Berl). 2001 Sep;157(3):243-53.

PMID:
11605079
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk